News & Blog

News

,

Press Releases

Biocytogen and Hansoh Pharma Announce an Antibody License Agreement

BEIJING, China, and Shanghai, China, January 3, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM HiTS Platforms and Hansoh Pharmaceutical Group Company Limited…

Keep Reading

Blog

TCR-Mimic Antibody Platform

Immunotherapy has made a great breakthrough in recent years, and antibody therapy is the core of this breakthrough. Traditional antibody therapies target cell membrane surface antigens (such as PD-1 and PD-L1) or soluble antigens. However, ideal tumor antigens (such as…

Keep Reading

Press Releases

Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-based Cell Therapy

Beijing and Guangzhou, China, September 15, 2022 — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody…

Keep Reading

Press Releases

Biocytogen Expands Partnership with Merck

Biocytogen Expands Partnership with Merck Beijing, China and Darmstadt, Germany, August 25, 2022 — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) entered into a global licensing agreement with Merck for the use of Biocytogen’s RenMice™ platform. Under the terms of the agreement, Merck…

Keep Reading

Press Releases

Biocytogen Enters into Antibody Agreement with Merck

BEIJING, CHINA, [April 29, 2022] – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck to grant them a sole license to evaluate Biocytogen’s proprietary antibodies against at least three distinct…

Keep Reading

Press Releases

Biocytogen Signs RenMab™/RenLite® Licensing Agreement with BeiGene

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) reached an agreement with BeiGene (Beijing) Co., Ltd. (“BeiGene”) (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen’s fully human antibody RenMab™/RenLite® mice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of…

Keep Reading